Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

BACKGROUND: In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effective as colistin plus IMI for the treatment of imipenem-nonsusceptible gram-negative infections. Differences in nephrotoxicity were observed between tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Michelle L, Motsch, Johann, Kaye, Keith S, File, Thomas M, Boucher, Helen W, Vendetti, Neika, Aggrey, Angela, Joeng, Hee-Koung, Tipping, Robert W, Du, Jiejun, DePestel, Daryl D, Butterton, Joan R, Paschke, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052751/
https://www.ncbi.nlm.nih.gov/pubmed/32154325
http://dx.doi.org/10.1093/ofid/ofaa054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052751/
https://www.ncbi.nlm.nih.gov/pubmed/32154325
http://dx.doi.org/10.1093/ofid/ofaa054

Ejemplares similares